Curated News
By: NewsRamp Editorial Staff
June 30, 2026

Silo Pharma Advances PTSD Treatment with Nasal Spray Study

Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • Silo Pharma advances SPC-15 for PTSD with robustness study, aiming for FDA guidance and a streamlined 505(b)(2) path.
  • Resyca will test Silo Pharma's microchip-based Soft-Mist Nasal Spray system consistency and SPC-15 stability over 30 days.
  • Silo Pharma develops SPC-15 for PTSD, aiming to improve mental health treatment with a prophylactic intranasal therapy.
  • Silo Pharma's drug-device partner Resyca studies a microchip nasal spray system for delivering PTSD treatment SPC-15.

Impact - Why it Matters

This news matters because PTSD affects millions worldwide, and current treatments often have limited efficacy or significant side effects. Silo Pharma's SPC-15, delivered via a novel microchip-based Soft-Mist Nasal Spray, represents a potential breakthrough in prophylactic treatment. The robustness study and planned FDA engagement signal progress toward clinical trials, offering hope for a more effective and convenient therapy. For investors, this milestone could de-risk the development pathway and highlight Silo's innovative approach in the biopharmaceutical space.

Summary

Silo Pharma (NASDAQ: SILO) is making strides in the development of SPC-15, its lead intranasal prophylactic treatment candidate for post-traumatic stress disorder (PTSD). The company announced that its drug-device development partner, Resyca, will conduct a robustness study of the microchip-based Soft-Mist Nasal Spray system used to deliver SPC-15. This study will evaluate the consistency of device performance and the stability of SPC-15 and placebo formulations over a 30-day period, which is crucial for supporting the combination product. The results are expected to bolster Silo’s planned FDA Type C meeting request, where the company intends to seek regulatory guidance on its investigational new drug (IND) strategy and Phase 1 clinical trial design. Silo previously aligned with the FDA on pursuing the streamlined 505(b)(2) regulatory pathway for SPC-15 following a pre-IND meeting.

Silo Pharma is a diversified developmental-stage biopharmaceutical company with a therapeutic focus on underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. Its portfolio includes innovative programs like SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo conducts its research in collaboration with leading universities and laboratories, as highlighted on its website at silopharma.com. Investors can stay updated with the latest news and updates relating to SILO in the company’s newsroom at https://nnw.fm/SILO.

To view the full press release, visit https://nnw.fm/Yzvx7. NetworkNewsWire (NNW), a specialized communications platform, distributed this news as part of its financial news and content services. NNW is part of the Dynamic Brand Portfolio @ IBN, offering services like press release distribution via InvestorWire, editorial syndication, and social media distribution. This press release underscores Silo Pharma’s commitment to advancing treatments for PTSD and other CNS conditions, with the upcoming study poised to move SPC-15 closer to clinical trials.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Silo Pharma Advances PTSD Treatment with Nasal Spray Study

blockchain registration record for this content.